Get the Stockscreener App
5.94
1.00%
-0.06
Ars Pharmaceuticals Inc stock is traded at $5.94, with a volume of 3.48M.
It is down -1.00% in the last 24 hours and down -43.64% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$6.00
Open:
$6
24h Volume:
3.48M
Relative Volume:
1.77
Market Cap:
$589.86M
Revenue:
$98.99M
Net Income/Loss:
$-197.98M
P/E Ratio:
-2.9675
EPS:
-2.0017
Net Cash Flow:
$-175.32M
1W Performance:
-15.14%
1M Performance:
-43.64%
6M Performance:
-41.82%
1Y Performance:
-66.85%
1-Day Range:
$5.76
$6.22
1-Week Range:
$5.76
$7.1407
52-Week Range:
$5.76
$18.63
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
5.94 | 589.86M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals Inc (SPRY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ARS Pharmaceuticals Inc (SPRY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
(SPRY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ARS passes the ball to Drew Brees in Neffy awareness campaign - Fierce Pharma
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Moomoo
Ars Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
ARS Pharmaceuticals, Inc. 8-K SEC Filing July 2026 – Company Info, Stock Symbol SPRY, and Nasdaq Listing - Minichart
ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc.SPRY - PR Newswire
Donn Casale Net Worth (2026) - GuruFocus
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO - Yahoo Finance
Pomerantz LLP investigates ARS Pharmaceuticals for possible securities fraud after stock drops 24%. - Pluang
Millennium group discloses ARS Pharmaceuticals (SPRY) ownership below 5% - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-07-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out | NDAQ:SPRY | Press Release - Stockhouse
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What's Going on With ARS Pharma Stock Thursday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
ARS Pharmaceuticals appoints Donn Casale as CEO - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirt - The National Law Review
ARS Pharmaceuticals: CEO Richard Lowenthal Will No Longer Serve as Employee and Officer, Effective July 6 - Moomoo
ARS Pharmaceuticals stock falls as CEO Lowenthal steps down By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Investors to Connect - ACCESS Newswire
ARS Pharmaceuticals appoints new CEO - MSN
ARS Pharmaceuticals Announces CEO Succession - Investing News Network
ARS Pharmaceuticals Names Casale CEO, Succeeding Co-Founder Lowenthal - Moomoo
ARS Pharmaceuticals names Donn Casale as new CEO By Investing.com - Investing.com South Africa
ARS Pharmaceuticals names Donn Casale as new CEO - Investing.com
ARS Pharmaceuticals stock falls as CEO Lowenthal steps down - Investing.com
ARS Pharmaceuticals Names Donn Casale as CEO as Richard Lowenthal Departs - Moomoo
ARS Pharmaceuticals: Donn Casale, Pres, Appointed CEO and Director >SPRY - Moomoo
Donn Casale becomes ARS Pharmaceuticals (SPRY) CEO and joins board through 2029 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ARS Pharmaceuticals stock plunges 23% after Nef... - Pluang
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals, Inc. (SPRY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ARS Pharmaceuticals (SPRY) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (SPRY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceu - The National Law Review
SPRY Should I Buy - Intellectia AI
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ARS Pharmaceuticals (SPRY) President awarded 898,456 long-term stock options - Stock Titan
ARS Pharmaceuticals plunges 23% as Neffy fails to secure insurance coverage - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud - Business Wire
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
(SPRY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer |
Jun 12 '26 |
Sale |
10.00 |
25,000 |
250,000 |
12,176 |
| Fitzpatrick Alexander A | Chief Legal Officer |
Jun 12 '26 |
Sale |
10.00 |
3,355 |
33,550 |
90,910 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):